Orchid Shares Plummet 27 Percent on Meek Q3 Revenues, Widened Losses

Oct 27, 2005

This article has been updated from an earlier version to include stock price.

NEW YORK, Oct. 27 (GenomeWeb News) - Shares in Orchid Cellmark were down 27.48 percent, or $2.30, at $6.07, in mid-afternoon trading after the company reported flat third-quarter revenues amid declining R&D spending and surging net losses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Main menu